trending Market Intelligence /marketintelligence/en/news-insights/trending/y_cvubsvdkretvcwlvakdw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Akcea gets US FDA advisory committee recommendation for genetic disease drug

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Akcea gets US FDA advisory committee recommendation for genetic disease drug

A U.S. Food and Drug Administration advisory committee recommended the approval of Akcea Therapeutics Inc.'s Waylivra.

Waylivra is meant to treat familial chylomicronemia syndrome, or FCS, a rare genetic disease characterized by a patient's inability to break down fat. There are no approved therapies for FCS, which is often misdiagnosed or goes undiagnosed, according to Akcea.

The recommendation from the FDA's Division of Metabolism and Endocrinology Products Advisory Committee will be taken into consideration alongside Akcea's new drug application for Waylivra, which has an Aug. 30 target action date.

The company's regulatory submission features data from two phase 3 clinical trials, as well as findings from an ongoing study. In one phase 3 trial, called Approach, Waylivra delivered a 77% mean reduction in triglycerides, a type of fat in the blood, and decreased risk of pancreatitis, which FCS patients often experience.

Akcea is unit of Ionis Pharmaceuticals Inc.